Larimar Therapeutics, Inc. (LRMR), Monday announced positive initial data from the long-term open label extension (OLE) study of nomlabofusp in participants with Friedreich's Ataxia.
Friedreich's ataxia is a genetic, progressive, neurodegenerative disorder.
Data from the OLE study showed that treatment with nomlabofusp raised frataxin levels in participants. Friedreich's ataxia is caused by frataxin deficiency, and increase in frataxin levels may lead to the slowing of progression of the disease.
The company added that it remains on track to initiate a registrational study of nomlabofusp in mid-2025. It plans to submit Biologics License Application (BLA) in the second half of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.